6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

5 trials found

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05152394 (ClinicalTrials.gov)	January 2022	29/11/2021	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Parkinson's Di ...	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusio ...	Parkinson Disease	Biological: AlloRx	The Foundation for Orthopaedics and Regenerative Medicine	NULL	Not yet recruiting	N/A	N/A	All	20	Phase 1	Antigua and Barbuda
2	NCT04912115 (ClinicalTrials.gov)	October 5, 2021	25/5/2021	Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dysk ...	A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of ...	Dyskinesias;Movement Disorders;Central Nervous System Diseases;Nervous System Diseases;Neurologic Ma ...	Drug: Ketamine;Drug: Midazolam	PharmaTher Inc.	NULL	Suspended	30 Years	85 Years	All	30	Phase 2	United States
3	NCT04064294 (ClinicalTrials.gov)	June 1, 2019	19/8/2019	Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors	Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins	Parkinson Disease;Dyskinesia, Drug-Induced	Drug: Intravenous Infusion	VA Office of Research and Development	Oregon Health and Science University	Recruiting	50 Years	N/A	All	120		United States
4	NCT02157714 (ClinicalTrials.gov)	June 2014	4/6/2014	Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered ...	Parkinson's Disease	Drug: PRX002;Other: Placebo	Prothena Biosciences Limited	Hoffmann-La Roche	Completed	40 Years	80 Years	Both	64	Phase 1	United States
5	NCT02095171 (ClinicalTrials.gov)	March 2014	14/3/2014	Single Ascending Dose Study of PRX002 in Healthy Subjects	A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered b ...	Parkinson's Disease	Drug: PRX002;Other: Placebo	Prothena Biosciences Limited	Hoffmann-La Roche	Completed	21 Years	65 Years	Both	40	Phase 1	United States

First Previous1Next Last